Substance / Medication

Osilodrostat

Overview

Active Ingredient
osilodrostat
RxNorm CUI
2286252

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

No related conditions have been mapped yet. Condition-intervention linkages are derived from SNOMED CT relationships and will expand as the knowledge graph grows.

Administration & Protocol

Dosing, route, and treatment protocol

Administration details including route, dosing schedules, preparation instructions, and contraindications are pending physician authorship.

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

2 trials linked to this intervention

2
Total Trials
2
Recruiting
0
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Osilodrostat dose impact on efficacy/safety in Cushing's disease: large, pooled analysis of LINC 2, 3, and 4.
Fleseriu Maria, Pivonello Rosario, Lacroix André et al. · Eur J Endocrinol · 2025
PMID: 41052284Trial
Randomized Trial of Osilodrostat for the Treatment of Cushing Disease.
Gadelha Mônica, Bex Marie, Feelders Richard A et al. · J Clin Endocrinol Metab · 2022
PMID: 35325149TrialFull text (PMC)
Efficacy and safety of osilodrostat in patients with Cushing's disease (LINC 3): a multicentre phase III study with a double-blind, randomised withdrawal phase.
Pivonello Rosario, Fleseriu Maria, Newell-Price John et al. · Lancet Diabetes Endocrinol · 2020
PMID: 32730798Trial
Osilodrostat: 11β-hydroxylase inhibitor for treatment of Cushing's disease.
Paton D P · Drugs Today (Barc) · 2020
PMID: 33185629Trial
Osilodrostat, a potent oral 11β-hydroxylase inhibitor: 22-week, prospective, Phase II study in Cushing's disease.
Fleseriu Maria, Pivonello Rosario, Young Jacques et al. · Pituitary · 2016
PMID: 26542280TrialFull text (PMC)

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Risk profile, common and serious adverse effects, contraindications, and drug interactions are pending physician authorship.

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Osilodrostat (substance)
SNOMED CT
863916001
UMLS CUI
C4330903
RxNorm CUI
2286252

Clinical Data

This intervention maps to 0 entities in the Ltrl knowledge graph.

0
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
2
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.